Ibandronate and periprosthetic bone mass: new therapeutic approach in periprosthetic loosening prevention

• Published in: Clinical cases in mineral and bone metabolism Vol. 8; no. 1; pp. 55 - 56
• Main Authors: Muratore, Maurizio, Quarta, Eugenio, Quarta, Laura, Grimaldi, Antonella, Orgiani, Antonio, Marsilio, Antonio, Rollo, Giuseppe
• Format: Journal Article
• Language: English
• Published: Italy CIC Edizioni Internazionali 01-01-2011
• Subjects: Original; periprosthetic bone loss; bisphosphonates; ibandronate
• ISSN: 1724-8914; 1971-3266

A prosthetic implant modifies the physiological transmission of loads to the bone, initiating a remodeling process.Studies of the mechanisms responsible for periprosthetic bone loss contributed to the definition of new pharmacological strategies that may prevent aseptic implant loosening. Bisphosphonates are a class of drugs useful to this purpose, and have been shown to be effective in reducing periprosthetic resorption during the first year after the implant. We aimed to assess the inhibitory effect on periprosthetic osteolysis of ibandronate, a highly potent aminobisphosphonate, administered orally and IV with an extended interval between doses and optimal treatment adherence. In view of the fact that periprosthetic remodeling takes place during the first 6-12 months after surgery and is ultimately responsible for prosthesis longevity, we may conclude that the administration of high dosage ibandronate postsurgery by IV bolus and subsequently as cyclic oral treatment reduced cortical osteopenia in the metaphyseal region, and in the calcar region of the proximal femur. This therapy might therefore be used as preventive measure against postsurgical osteopenia and probably also against aseptic loosening.